Uneek Mehra - 26 Aug 2025 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)

Role: Chief Financial Officer
Signature: /s/ Aaron Chan, Attorney-in-Fact
Issuer symbol: HLXB
Transactions as of: 26 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 28 Aug 2025, 16:34:54 UTC
Previous filing: 18 Aug 2025
Next filing: 12 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Mehra Uneek	Chief Financial Officer	BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO	/s/ Aaron Chan, Attorney-in-Fact	28 Aug 2025	0001881504

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BBOT	Stock Option (Right to Buy)	Award	$0	+633,570		$0.000000	633,570	26 Aug 2025	Common Stock	633,570	$9.59	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares underlying such option shall vest on July 21, 2026, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date.